Industry Insights · Artificial Heart & Circulatory Support
China's artificial hearts: implantable + percutaneous, and how materials gatekeep
Heart failure is the end stage of cardiovascular disease — over 64M patients globally, 15M+ in China, 1.7M+ end-stage — while heart transplants number only ~1,000 a year, a vast donor gap. Ventricular assist devices (VADs) mechanically assist or replace the heart's pumping and are stretching from single end-stage therapy to full-course coverage. From a materials view serving medical devices, we care most about the floor: how materials gatekeep blood contact and long-term implantation.
Why the field rose: the heart-failure imperative
The core tension in end-stage heart failure is that donors fall far short — only ~1,000 transplants a year against millions of end-stage patients. VADs mechanically assist or replace the heart's pumping as a core way to extend life, and have reached third-generation full-maglev technology, cutting blood damage and complications. That hard demand is the underlying reason the field took off.
The landscape: an implantable + percutaneous dual track
The two product types cover different stages of heart failure, complementary rather than substitutes:
- Implantable (e.g. Corheart®6, 90 g/34 mm): long-term end-stage support/replacement; five products approved in China, with Core Medical taking share fast on miniaturisation;
- Percutaneous (e.g. CorVad®4.0): transfemoral minimally invasive placement for short-term circulatory support in high-risk PCI and acute cardiogenic shock; Core Medical won the first domestic approval in December 2025, versus a global market previously led by J&J's Impella, leaving wide room for domestic substitution.
Materials view: gatekeeping long-term blood contact
The artificial heart is among the most demanding Class III devices for reliability and hemocompatibility: in long-term contact with blood, anti-thrombus and anti-hemolysis surfaces and flow paths, and long-term material stability, bear directly on safety. The industry's challenges concentrate here too — accumulating long-term clinical data, commercialisation and profitability pressure (leading players posted cumulative losses of several hundred million RMB over 2023–2025), payment and insurance coverage, and clinician/patient education. For material supply, the more long-term and blood-contacting the use, the more it demands biocompatibility data, lot traceability and complete documentation. BIO's role is to make the medical-grade materials line solid: selectable, documented, traceable.
The BIO angle
FAQ
What is a VAD?
A ventricular assist device mechanically assists or replaces the heart's pumping; it is a core way to extend life in end-stage heart failure amid donor shortage, and has reached third-generation full-maglev technology.
What is the difference between implantable and percutaneous?
Implantable handles long-term end-stage support/replacement (e.g. Corheart®6); percutaneous is placed via the vasculature for short-term support in high-risk procedures and acute cardiogenic shock (e.g. CorVad®4.0), covering different stages of heart failure.
Why are materials so critical?
Artificial hearts contact blood long-term; anti-thrombus/hemolysis surfaces and flow paths, plus long-term material stability, bear directly on safety, making long-term clinical data and biocompatibility documentation the key challenge.
Related reading
- Carmat Aeson Total Artificial Heart: Design and Materials of the EU's Only Commercial TAH | BIO Insights
- Percutaneous RVAD Enters the Fast Track: the Overlooked Right Heart and a Materials Barrier | BIO Insights
- China's Maglev Artificial Heart: from First Implant to the Global High-End Market | BIO Insights
Note: an original analysis compiled from public industry information; figures and conclusions per official/original sources. Not investment advice.
Building in China's medical-device market?
From advanced medical silicone/polymers to material selection, regulatory and supply, BIO helps global and local partners move from selection to landed supply in China.